|
Synonyms: Arzerra® | GSK 1841157 | GSK1841157 | humax-CD20 | Kesimpta® (subcutaneous) | OMB-157 | OMB157
ofatumumab is an approved drug (FDA (2009), EMA (2010))
Compound class:
Antibody
Comment: Ofatumumab is a type I anti-CD20 monoclonal, designed to target surface CD20 on B-lymphocytes.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖
View more information in the IUPHAR Pharmacology Education Project: ofatumumab |
| Immunopharmacology Comments |
| Binding of ofatumumab to the membrane-proximal epitope of CD20 induces recruitment and activation of the complement pathway at the cell surface. This leads to complement-dependent cytotoxicity which results in lysis of tumour cells. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Chronic lymphocytic leukemia |
Disease Ontology:
DOID:1040 OMIM: 151400 Orphanet: ORPHA67038 |
Approved drug for some CLL patients. | |
